How AI Helped Get the Right Treatment to Cancer Patients
When biopharma companies apply data and analytics, they can make smarter commercial decisions, get better treatment information to physicians, and help save lives.
Branże biotechnologii oraz farmaceutyki kontynuują swoją szybką ewolucję cyfrową. Siły geopolityczne oraz ekonomiczne stanowią jednak dla nich przeszkody, które wymagają precyzyjnej strategii w całym łańcuchu dostaw. Poznaj świadome przywództwo BCG w dziedzinie biofarmaceutyków, by uzyskać informacje na temat przyszłości branży biotechnologicznej.
When biopharma companies apply data and analytics, they can make smarter commercial decisions, get better treatment information to physicians, and help save lives.
A recent analysis shows disturbing variations in the use of a key diagnostic for lung cancer patients. Adopting new protocols and tools can lead to better care.
New technologies are transforming the pharmaceutical industry’s approach to R&D. What’s happening now in the field—and what’s coming next?
The revolution has come to health care. Artificial intelligence has major repercussions for players across the industry—as well as for new-technology entrants and consumers.
Launching an orphan treatment is more complicated than ever. Here’s how to successfully navigate the challenges.
Given the growing complexity of customers’ needs and other sales challenges, pharma companies should activate six sales force roles.
“Double down on your loyalists”—and other insights to improve sales team efficiency.
Although women make up the majority of health care employees, men still dominate the corner office. Here are six ways to give women a fair shot at the top.
Even highly regulated and rigid industries can benefit from new ways of working.
BCG’s 2019 benchmark study found that companies need to relentlessly manage the elements that demand the greatest spending—internal and contract manufacturing.
Supply chain managers need to ask certain key questions about how the new law will affect their companies’ global networks, investments, and M&A strategies—giving them a better understanding of how to make winning moves.
Companies are eager to shift more of the production they outsource to trusted strategic partners, but doing that right takes analysis and planning.
These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.
The most successful companies are those with flexible R&D allocation, according to BCG’s Michael Ringel in an article published in Nature Reviews Drug Discovery. These companies actively pursue and invest in the right new scientific opportunities, balance quantitative and qualitative information on scientific feasibility and market need, employ incentives that drive “truth seeking,” and introduce variability into the cost base to enable flexibility in year-to-year investment levels.
SUBSCRIBE
PL
Ta strona korzysta z plików "cookies" w celu poprawienia funkcjonalności i działania. Decydując się na dalsze korzystanie z tej strony, jednocześnie zgadzasz się z użyciem plików "cookies" przez tą stronę. Zobacz naszą Politykę Cookies, żeby dowiedzieć się więcej.